Previous immunohistochemical analysis showed a bimodal distribution in estrogen receptors (ER) expression ---- the majority of breast cancer patients express either ER-negative (low expression) or unambiguously ER-positive (high expression), of which (~80%) are ER+, while moderate ER immunostaining is rarely observed [40]. Here, ESR1 is linked to breast carcinoma.